Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 4, 2009, Pages 611-614

  Hirai, Yoshimitsu ^a   Yoshimasu, Tatsuya ^a   Oura, Shoji ^a   Tamaki, Takeshi ^a   Ota, Fuminori ^a   Nakamura, Rie ^a   Shimizu, Yukio ^a   Naito, Koma ^a   Ota, Megumi ^a   Miyasaka, Miwako ^a   Okamura, Yoshitaka ^a   Nakamura, Yasushi ^a   Yasuoka, Hironao ^a   Kodama, Rieko ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; ERCC1; HDRA; Non small cell lung cancer

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MITOMYCIN C; NAVELBINE; PACLITAXEL;

ARTICLE; ASSAY; CANCER ADJUVANT THERAPY; CANCER SURGERY; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; TISSUE CULTURE;

EID: 79959840665     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Olaussen KA, Dunant A, Fouret P, et al: IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983-991, 2006. (Pubitemid 44343542)
2. Douillard JY, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage I B-III A non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7(9):719-727, 2006.
3. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352(25):2589-2597, 2005. (Pubitemid 41007845)
4. Yoshimasu T, Oura S, Hirai I, et al: Data acquisition for the histoculture drug response assay in lung cancer. J Thorac Cardiovasc Surg 133(2):303-308, 2007. (Pubitemid 46136244)
5. Rosell R, Taron M, Barnadas A, et al: Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Control 10(4):297-305, 2003. (Pubitemid 36919542)
6. Martin LP, Hamilton TC and Schilder RJ: Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14(5):1291-1295, 2008 (Review). (Pubitemid 351413906)
7. Henning W and Stuerzbecher H-W: Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 193:91-109, 2003.
8. Ohnishi T, Taki T, Hiraga S, et al: In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophys Res Commun 245:319-324, 1998.
9. Qiao GB, Wu YL, Yang XN, et al: High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 93(1):137-143, 2005.
10. Simon GR, Sharma S, Cantor A, et al: ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127(3):978-983, 2005. (Pubitemid 40775532)
11. Takenaka T, Yoshino I, Kouso H, et al: Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 121(4):895-900, 2007. (Pubitemid 47106222)
12. Shimizu J, Horio Y, Osada T, et al: mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology 13(4):510-517, 2008.
13. Cobo M, Isla D, Massuti B, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression-a phase III trial in non-small-cell lung cancer. J Clin Oncol 25(19):2747-2754, 2007. (Pubitemid 47123183)